QIAGEN Launches QIAsymphony Connect Amid Strong Second-Quarter Performance
On August 27, 2026, QIAGEN N.V. (NYSE:QGEN) introduced the QIAsymphony Connect platform for clinical nucleic acid extraction, following a strong second-quarter performance that exceeded its guidance. The new system builds on an existing installed base of over 3,300 placements and uses familiar reagents to ease adoption in labs conducting oncology, infectious disease, and liquid biopsy tests. QIAGEN reported Q2 net sales of $535 million, flat compared to the prior year but above expectations for a decline. Growth areas like Sample technologies and QIAcuity drove performance with high single-digit consumables growth and mid-single-digit instrument growth. The company also raised its 2026 dividend by 40%. Despite these gains, some segments underperformed due to declining demand in US immigration testing for QuantiFERON and a tough comparison period for QIAstat-Dx respiratory tests. Management noted ongoing challenges with U.S. instrument spending and margin pressures from currency fluctuations.
Tickers: $QGEN